International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 6 November-December 2024 Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 6
November-December 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Recent Advances and Future Directions in the Management of Metastatic Castration-Resistant Prostate Cancer using Androgen Receptor Signaling Inhibitors and Poly-adipose Polymerase Inhibitors: a Literature Review

Author(s) Muhammad Rayyan Faher Shahab, Nouval Shahab
Country Indonesia
Abstract Prostate cancer is still the most common cancer in men and the second leading cancer-related cause of death in men worldwide. There are several types of prostate cancer. One of which is the metastatic progression of castration-resistant prostate cancer (mCRPC). According to current studies, the mechanism of resistance can be categorized into classical androgen receptor (AR) pathway overexpression, abnormal AR pathway activation, and non-AR pathway. These mechanisms develop overtime to further induce treatment resistance in mCRPC. Development of novel therapeutic treatments is necessary to tackle this issue. Recent studies have been conducted on the combination therapy of androgen receptor signaling inhibitors (ARPi) and poly (ADP-ribose) polymerase inhibitors (PARPi) in treating mCRPC shows a nuanced perspective regarding its efficacy compared to monotherapy. Studies shows the combination therapy has significantly prolong radiographic progression-free survival (rPFS) compared to monotherapy in certain genetic groups. Further research is necessary to fully understand their role in the broader mCRPC treatment landscape.
Keywords prostate cancer, castration-resistant, androgen receptor signaling inhibitors, poly (ADP-ribose) polymerase inhibitors
Field Medical / Pharmacy
Published In Volume 6, Issue 2, March-April 2024
Published On 2024-04-24
Cite This Recent Advances and Future Directions in the Management of Metastatic Castration-Resistant Prostate Cancer using Androgen Receptor Signaling Inhibitors and Poly-adipose Polymerase Inhibitors: a Literature Review - Muhammad Rayyan Faher Shahab, Nouval Shahab - IJFMR Volume 6, Issue 2, March-April 2024. DOI 10.36948/ijfmr.2024.v06i02.18256
DOI https://doi.org/10.36948/ijfmr.2024.v06i02.18256
Short DOI https://doi.org/gtsg6r
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 6Cover Page Vol 6 Isu 5Cover Page Vol 6 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com